RY 170.06 -0.4391% SHOP 146.45 -0.0137% TD 78.54 0.4605% ENB 63.205 1.1766% BN 79.82 0.9741% TRI 221.22 -0.8738% CNQ 45.03 -0.9241% CP 106.44 0.2354% CNR 143.84 -0.3326% BMO 140.27 0.5808% BNS 73.51 0.9753% CSU 4258.9448 -0.9172% CM 88.77 -0.3144% MFC 42.81 0.6584% ATD 74.89 -0.4784% NGT 57.67 2.2155% TRP 66.61 0.6954% SU 56.91 0.3173% WCN 252.55 -0.7038% L 176.59 -2.6301%

Delivra Health Brands Inc.

Healthcare CA DHB

0.015CAD
-(-%)

Last update at 2025-01-14T14:30:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.010.06
LowHigh

Fundamentals

  • Previous Close 0.01
  • Market Cap6.25M
  • Volume50000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA0.60M
  • Revenue TTM12.38M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM 4.82M
  • Diluted EPS TTM-

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Income before tax -0.18400M -7.00900M -22.67200M -58.73500M
Minority interest - - 0.00000M 1.54M
Net income -0.18400M -7.00900M -28.53800M -79.85700M
Selling general administrative 4.86M 6.50M 8.89M 13.90M
Selling and marketing expenses - - - -
Gross profit 4.82M 2.60M 1.92M 0.72M
Reconciled depreciation 1.33M 2.12M 2.66M 3.07M
Ebit - - - -
Ebitda - - - -
Depreciation and amortization - - - -
Non operating income net other - - - -
Operating income -1.36300M -6.01200M -9.26000M -15.69200M
Other operating expenses - - - -
Interest expense 0.25M 0.64M - 0.80M
Tax provision - - - -
Interest income - - 0.04M -
Net interest income -0.25000M -0.63500M 0.04M -0.79900M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense - - - -
Total revenue 9.79M 8.14M 7.96M 7.78M
Total operating expenses 11.15M 14.15M 17.22M 23.47M
Cost of revenue 4.97M 5.54M 6.04M 7.06M
Total other income expense net 1.43M -0.36200M -13.45300M -42.24400M
Discontinued operations - - - -
Net income from continuing ops -0.18400M -7.00900M -22.67200M -58.73500M
Net income applicable to common shares - - - -
Preferred stock and other adjustments - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 10.56M 11.59M 19.06M 57.84M
Intangible assets 2.47M 3.67M 6.03M 12.63M
Earning assets - - - -
Other current assets - - - -
Total liab 7.17M 8.21M 9.09M 21.27M
Total stockholder equity 3.39M 3.37M 9.98M 33.52M
Deferred long term liab - - - -
Other current liab - - - 0.75M
Common stock - - - -
Capital stock 148.23M 148.23M 148.23M 146.20M
Retained earnings -170.03800M -169.85400M -162.84500M -134.30700M
Other liab - - - -
Good will - - - 0.00000M
Other assets - - - -
Cash 2.72M 1.08M 4.43M 1.41M
Cash and equivalents - - - -
Total current liabilities 5.47M 6.54M 7.24M 19.19M
Current deferred revenue - - - -
Net debt - 1.02M - 4.57M
Short term debt - - - -
Short long term debt 0.25M 0.44M 0.31M 3.89M
Short long term debt total - - - -
Other stockholder equity - - - -
Property plant equipment - - - -
Total current assets 7.92M 7.49M 9.84M 28.41M
Long term investments - - - 0.00000M
Net tangible assets - - - -
Short term investments 0.01M 0.03M 0.71M 0.00000M
Net receivables 2.38M 1.38M 1.26M 1.34M
Long term debt 1.70M 1.67M 1.85M 2.08M
Inventory 2.26M 2.22M 2.28M 9.29M
Accounts payable 2.19M 3.58M 4.87M 10.74M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - - - -
Deferred long term asset charges - - - -
Non current assets total 2.65M 4.10M 9.23M 29.43M
Capital lease obligations - - - -
Long term debt total - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments 2.91M 1.35M 12.27M -3.63600M
Change to liabilities - - - -
Total cashflows from investing activities - - - -
Net borrowings - - - -
Total cash from financing activities -0.25500M -0.30900M 0.45M 3.17M
Change to operating activities - - - -
Net income -0.18400M -7.00900M -28.53800M -79.85700M
Change in cash 1.64M -3.34700M 3.02M -18.89500M
Begin period cash flow 1.08M 4.43M 1.41M 20.30M
End period cash flow 2.72M 1.08M 4.43M 1.41M
Total cash from operating activities -1.08800M -4.44100M -9.64700M -18.35900M
Issuance of capital stock - 0.00000M 4.49M -
Depreciation 1.33M 2.12M 2.66M 3.07M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory -0.46700M -0.71700M 2.27M -6.36500M
Change to account receivables - - - -
Sale purchase of stock - - - -
Other cashflows from financing activities - - - -
Change to netincome - - - -
Capital expenditures 0.04M 0.02M 0.03M 6.32M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -1.37600M -1.30700M -2.24600M -3.86700M
Stock based compensation 0.15M 0.35M 0.58M 2.02M
Other non cash items 0.07M 0.25M 0.27M -1.61400M
Free cash flow -1.12900M -4.46300M -9.68000M -24.67400M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DHB
Delivra Health Brands Inc.
- -% 0.01 - - 0.51 1.20 0.33 1.73
RX
Biosyent Inc.
-0.3 2.68% 10.90 18.58 15.70 3.82 3.65 3.34 11.28
LOVE
Cannara Biotech Inc
- -% 0.84 11.00 - 0.77 0.73 1.34 6.59
ZYUS
ZYUS Life Sciences Corporation
- -% 0.82 - - 135.51 3.73 157.30 -4.258
LSL
LSL Pharma Group Inc.
-0.01 2.56% 0.38 - - 3.91 2.88 4.85 636.87

Reports Covered

Stock Research & News

Profile

Delivra Health Brands Inc., through its subsidiaries, provides lifestyle, health, and wellness products to consumers and patients worldwide. The company offers cannabis, liquid sleep shots, sleep powder packets, gummies, and pain relief creams. It sells its products under LivRelief, Dream Water, and LivRelief infused brands. The company was formerly known as Harvest One Cannabis Inc. Delivra Health Brands Inc. is headquartered in Vancouver, Canada.

Delivra Health Brands Inc.

999 Canada Place, Vancouver, BC, Canada, V6C 3E2

Key Executives

Name Title Year Born
Mr. Frank A. Holler MBA Independent Exec. Chairman 1957
Mr. Gord Davey Pres, CEO & Director NA
Mr. Jack Z. Tasse C.M.A., CPA CFO & Corp. Sec. NA
Mr. Matthew Wagar Sr. VP of Marketing & Innovation NA
Ms. Ann Gallery Sr. VP of Corp. Communications NA
Mr. Will Stewart Sr. VP of Corp. & Public Affairs 1976
Mr. Christopher Podolsky CA, CPA Advisor NA
Mr. Jonathan David Hartshorn Pres & CEO of Satipharm 1970
Mr. Kwong Choo CGA, CPA VP of Fin. 1964
Mr. Frank A. Holler MBA Independent Executive Chairman 1957

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.